Hacked by islam_Bey imhatimi.org

Ranbaxy Laboratories Ltd has informed BSE that the Company and Orchid Chemicals & Pharmaceuticals Ltd (Orchid) on April 22, 2008 has announced that they have entered into a Business Alliance Agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients. Additionally, this agreement would establish a framework for enhanced future co-operation between the two Companies.

Speaking on the development, Mr. Malvinder Mohan Singh, CEO & MD, Ranbaxy, said, “Orchid is a niche player in the global pharmaceutical industry with an impressive track record, particularly in sterile products. We are pleased to enter into this long term strategic alliance with Orchid. The agreement will be mutually beneficial and synergistic, allowing both organisations to leverage each others inherent strengths”.

Commenting on the alliance, Mr. K Raghavendra Rao, Managing Director, Orchid, said, “We are happy to join hands with Ranbaxy, India’s largest pharmaceutical Company. Ranbaxy’s global scale and market reach and Orchids state-of-the-art development and manufacturing capabilities would expand the business of both Companies. We believe that this will be a win-win arrangement for both Companies”.

Ranbaxy Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 28, 2008, inter-alia, for consideration of Audited Accounts for the year ended December 31, 2007 and recommendation of final dividend on Equity Shares for the year ended December 31, 2007.

Ranbaxy Laboratories Ltd on March 18, 2008 has annouced an exclusive in-licensing agreement with CD Pharma to market the INERSAN* brand in India and Nepal. The patented product, a probiotic preparation, is used for the treatment of dental problems such as Periodontitis, Gingivitis and Halitosis. Presently there is no particular drug available for the treatment of this dental problem. INERSAN, a natural biological product, shall be a first-of-its-kind to be introduced in India.

Commenting on the development, Sanjeev I Dani, Senior Vice President and Regional Director Asia & CIS, Ranbaxy, said “In the post patent era, we are driven by the need to in-license differentiated products and introduction of INERSAN tablets consolidates Ranbaxy’s position in Dental segment.” He also added that Periodontitis, Gingivitis and Halitosis are common Dental problems which if ignored, can lead to more serious complications. Dental practitioners in India currently do not have any specialized prescription product for these conditions and INERSAN tablets address this need for the segment.”

Early-stage Periodontitis (Gum Disease) is painful and causes swollen and bleeding gums. This can lead to serious infection and eventually may cause tooth loss if left untreated. Some dentists recommend surgical options such as flap surgery, soft tissue grafting or bone grafting and guided tissue regeneration.

Studies carried out over the years have shown that gum disease can affect a person’s overall health. Women with advanced gum diseases are likely to give birth to an underweight or pre-term baby while the ability of oral microbes to cross the placental barrier can expose the fetus to infection. Cardiac ailment patients have to be more careful to avoid Periodontitis because the bacteria from the mouth can cause clotting problems in the cardiovascular system and increase the risk of fatal heart attacks.